Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide.
We report the use of inhaled prostacyclin (PGI(2)) in 4 neonates with persistent pulmonary hypertension and hypoxemia refractory to inhaled nitric oxide. Oxygenation rapidly improved after inhalation of PGI(2) in all infants. The condition of one infant subsequently deteriorated, and alveolar capillary dysplasia was found at autopsy. The surviving infants were discharged with normal oxygen saturations in room air.
Kelly
Lisa K
LK
Department of Pediatrics, Children's Memorial Hospital and Northwestern University Medical School, Chicago, Illinois 60614, USA.
Porta
Nicolas F m
NF
Goodman
Denise M
DM
Carroll
Christopher L
CL
Steinhorn
Robin H
RH
D000280:Administration, Inhalation; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D011464:Epoprostenol / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D009569:Nitric Oxide / Q000008:administration & dosage* / Q000627:therapeutic use; D010547:Persistent Fetal Circulation Syndrome / Q000188:drug therapy*; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000627:therapeutic use
D000959:Antihypertensive Agents; D014665:Vasodilator Agents; D009569:Nitric Oxide; D011464:Epoprostenol